This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In May 2024, the Brazilian Senate Committee on Science, Technology, Innovation, and Informatics hosted two public hearings to discuss implementing Regulatory Data Protection (RDP) for pharmaceutical products of human use. The call for hearings (REQ 27/2023) was presented by Senator Izalci Lucas (Liberal Party).
recently in Novartis Pharmaceuticals Corp. Accord Healthcare Inc. But in Novartis Pharmaceuticals v. Accord Healthcare, neither of the panel members in the majority of the original opinion even agreed to rehear the case, let alone agreed to reverse their prior ruling. Talk about snatching victory from the jaws of defeat!
Supreme Court’s reasoning in Helsinn Healthcare v. Teva Pharmaceuticals (2019), the Federal Circuit rejected Celanese’s contentions that statutory changes wrought by the America Invents Act (AIA) altered the on-sale bar such that sales of products manufactured by an undisclosed process would not invalidate patents claiming that process.
Thorrun’s unique journey highlights the intriguing intersection of healthcare and legal expertise, demonstrating that the boundaries of traditional career paths can be fluid and dynamic. Her experience in healthcare advisory law particularly in the area of inquests. Join us now on your favourite podcast streaming app!
Court of Appeals for the Federal Circuit issued a precedential decision in Novartis Pharmaceuticals Corp. Accord Healthcare, Inc. Earlier today, the U.S. granting a petition for rehearing from appellant HEC Pharm Co.,
The report also underscores the agencies’ strengthened enforcement efforts, with 28 merger challenges in key sectors like healthcare, technology, and consumer goods. These enforcement actions targeted critical sectors, including pharmaceuticals, healthcare, technology, and energy. of the total.
The technology, healthcare, and financial services sectors continue to be the most active in corporate transactions, each influenced by unique market drivers, regulatory challenges, and digital transformation initiatives. Companies must now demonstrate how acquisitions will not result in market monopolization or unfair competitive advantages.
On April 29, the United States Court of Appeals for the Federal Circuit (CAFC) affirmed in part, reversed in part, vacated in part, and remanded a decision of the United States District Court for the Northern District of Illinois regarding alleged infringement by U.S. Venture Inc., Sunoco).
Healthcare and Pharma Consolidation: With regulatory shifts and technological advancements in biotech, pharmaceutical mergers are increasing, driven by both innovation and cost-saving incentives.
The disruption led to operational challenges across various sectors, including aviation, finance, and healthcare. Legal Turmoil in the Pharmaceutical Industry: AbbVie, Purdue, and Beyond” examines ongoing legal battles within the pharmaceutical industry, focusing on AbbVie’s petition to the U.S.
Evaluating AI Compliance: The LatticeFlow LLM Checker and the EU AI Act AI systems now make critical decisions that affect millions of lives, from healthcare to finance, raising urgent concerns about bias, security, and ethical integrity. Read the update. Read the update.
They had pharmaceutical companies, chemical companies, oil and gas companies, you name it, I have them as my clients. And then I moved to their sales and marketing team, traveling the country training folks on how to search the Chemical Abstracts databases. And it didn’t matter what the what the company was all about.
IPWatchdog LIVE opened today with a sneak preview of the latest episode of the IPWatchdog Unleashed podcast, which will be published Monday, and where IPWatchdog Founder and CEO Gene Quinn will examine the current state of the U.S.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content